300147 ST香雪制药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入817,994-25.40%1,858,6622,299,2882,187,0702,970,576
减:营业总成本991,852-16.38%2,266,7422,452,4742,575,6693,167,436
    其中:营业成本584,656-20.36%1,405,8071,509,5211,643,1732,189,989
               财务费用136,10521.78%231,011241,471212,510202,750
               资产减值损失(23,023)2,158.36%(380,109)(163,342)(138,578)(482,077)
公允价值变动收益348-705.00%6362,728(12)15,641
投资收益728-114.43%(6,000)(50,640)47,32933,589
    其中:对联营企业和合营企业的投资收益(235)-24.37%(1,343)(52,159)903(19,543)
营业利润(184,188)118.67%(784,525)(332,716)(464,142)(575,277)
利润总额(216,929)87.48%(842,071)(388,951)(511,864)(622,344)
减:所得税费用735-85.80%19,15412,795(7,215)24,458
净利润(217,664)80.07%(861,224)(401,746)(504,648)(646,801)
减:非控股权益16,21013.03%(2,664)(12,782)25,41029,772
股东净利润(233,874)72.96%(858,560)(388,964)(530,058)(676,573)

市场价值指针
每股收益 (元) *-0.35075.00%-1.300-0.590-0.800-1.020
每股派息 (元) *------------
每股净资产 (元) *1.242-54.12%1.5952.9113.6374.454
审计意见 #--标准的无保留意见保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容